Clinical characteristics of the FARIVE verification study
| . | 603 Cases . | 597 Controls . | ||
|---|---|---|---|---|
| Variables . | N . | Freq. . | N . | Freq. . |
| Localization of the thrombosis | ||||
| DVT, lower limbs | 102 | 0.28 | ||
| PE | 147 | 0.41 | ||
| DVT and PE | 105 | 0.3 | ||
| Gender and biometry | ||||
| Gender, women | 363 | 0.60 | 340 | 0.57 |
| Age, y (mean ± SD and range) | 53.1 ± 19.7 | (17-91) | 51.2 ± 18.4 | (18-89) |
| Height, m (mean ± SD and range) | 1.68 ± 0.9 | (1.48-2) | 1.68 ± 0.9 | (1.48-2.00) |
| BMI, kg/m2 (mean ± SD and range) | 26.5 ± 5.6 | (15-55) | 25.9 ± 6 | (15-47) |
| Obese, BMI ≥30 kg/m2 | 135 | 0.22 | 114 | 0.19 |
| Cardiovascular risk factors | ||||
| Hypertension* | 194 | 0.32 | 247 | 0.42 |
| Hyperlipidemia* | 156 | 0.26 | 134 | 0.22 |
| Diabetes mellitus* | 40 | 0.07 | 103 | 0.17 |
| Current smoking† | 100 | 0.17 | 138 | 0.24 |
| Family history | ||||
| VTE, first-degree relative | 145 | 0.24 | NA | |
| Provoked risk factors‡ | ||||
| Trauma | 24 | 0.04 | NA | |
| Cast, orthosis | 22 | 0.04 | NA | |
| Surgery | 109 | 0.18 | NA | |
| Pregnancy, postpartum 3 mo | 21 | 0.03 | NA | |
| Hormonal use (women only) | ||||
| Contraceptives§ | 146 | 0.40 | NA | |
| Menopausal replacement therapy§ | 28 | 0.08 | NA | |
| Sampled at study entry# | 587 | 0.97 | ||
| Warfarin treatment effect | ||||
| PK INR < 1.2 | 253 | 0.43 | ||
| PK INR 1.2-1.99 | 176 | 0.30 | ||
| PK INR 2.0-5.0 | 145 | 0.25 | ||
| Missing value | 13 | 0.02 | ||
| . | 603 Cases . | 597 Controls . | ||
|---|---|---|---|---|
| Variables . | N . | Freq. . | N . | Freq. . |
| Localization of the thrombosis | ||||
| DVT, lower limbs | 102 | 0.28 | ||
| PE | 147 | 0.41 | ||
| DVT and PE | 105 | 0.3 | ||
| Gender and biometry | ||||
| Gender, women | 363 | 0.60 | 340 | 0.57 |
| Age, y (mean ± SD and range) | 53.1 ± 19.7 | (17-91) | 51.2 ± 18.4 | (18-89) |
| Height, m (mean ± SD and range) | 1.68 ± 0.9 | (1.48-2) | 1.68 ± 0.9 | (1.48-2.00) |
| BMI, kg/m2 (mean ± SD and range) | 26.5 ± 5.6 | (15-55) | 25.9 ± 6 | (15-47) |
| Obese, BMI ≥30 kg/m2 | 135 | 0.22 | 114 | 0.19 |
| Cardiovascular risk factors | ||||
| Hypertension* | 194 | 0.32 | 247 | 0.42 |
| Hyperlipidemia* | 156 | 0.26 | 134 | 0.22 |
| Diabetes mellitus* | 40 | 0.07 | 103 | 0.17 |
| Current smoking† | 100 | 0.17 | 138 | 0.24 |
| Family history | ||||
| VTE, first-degree relative | 145 | 0.24 | NA | |
| Provoked risk factors‡ | ||||
| Trauma | 24 | 0.04 | NA | |
| Cast, orthosis | 22 | 0.04 | NA | |
| Surgery | 109 | 0.18 | NA | |
| Pregnancy, postpartum 3 mo | 21 | 0.03 | NA | |
| Hormonal use (women only) | ||||
| Contraceptives§ | 146 | 0.40 | NA | |
| Menopausal replacement therapy§ | 28 | 0.08 | NA | |
| Sampled at study entry# | 587 | 0.97 | ||
| Warfarin treatment effect | ||||
| PK INR < 1.2 | 253 | 0.43 | ||
| PK INR 1.2-1.99 | 176 | 0.30 | ||
| PK INR 2.0-5.0 | 145 | 0.25 | ||
| Missing value | 13 | 0.02 | ||